What are the management options for poor appetite in an adult patient with a BMI of 18.6 who is taking oxycodone, pregabalin, duloxetine, and buspirone?

Management of Poor Appetite in Underweight Patient on Multiple CNS Medications

First, systematically address medication-induced appetite suppression by reviewing and potentially reducing or discontinuing duloxetine, pregabalin, and oxycodone, as these agents commonly cause decreased appetite and nausea, then consider adding mirtazapine as it serves dual purposes of treating potential underlying depression/anxiety while stimulating appetite and weight gain.

Immediate Medication Review and Optimization

Address Medication-Induced Appetite Suppression

Your patient's current regimen contains multiple appetite-suppressing agents that require urgent evaluation:

• Duloxetine: Causes decreased appetite (10% incidence), nausea (18% incidence), and weight loss (14% experienced clinically significant ≥3.5% weight loss in trials) 1
• Oxycodone: Opioids are well-recognized contributors to nausea, constipation, and excessive drowsiness—all "nutrition impact symptoms" that directly impair oral intake 2
• Pregabalin: Can cause reduced consciousness, depression/anxiety, and gastrointestinal disturbances that may impair appetite 3

Critical Action: Minimize sedating medications and avoid polypharmacy, as retrospective studies demonstrate that reducing these factors helps mitigate nutrition impact symptoms like excessive drowsiness and fatigue 2

Treat Contributing Nutrition Impact Symptoms

Address reversible causes systematically 2, 4:

• Pain management: Optimize opioid dosing to balance analgesia with side effects; consider opioid rotation if excessive sedation or nausea persists
• Constipation: Initiate or optimize laxative regimen (common with opioids and duloxetine)
• Nausea: Consider metoclopramide for early satiety and nausea 2
• Depression/anxiety: Buspirone addresses anxiety but has no appetite-stimulating properties 5

Pharmacological Appetite Stimulation Strategy

First-Line Recommendation: Mirtazapine

Add mirtazapine as it provides the strongest evidence for appetite stimulation in your clinical context:

• Demonstrates significant appetite-stimulating and weight-gain properties, particularly beneficial in underweight older adults 6, 7
• Underweight older patients are more likely to receive mirtazapine than any other antidepressant in clinical practice 7
• Addresses potential underlying depression/anxiety while simultaneously treating poor appetite
• Can be dosed at bedtime (7.5-15 mg initially) to leverage sedating effects and minimize daytime somnolence

Important caveat: Inpatient studies show only numerical improvements in meal intake (mean 17.12% increase) without statistically significant differences between appetite stimulants 8. However, 48% of patients experienced documented improvement in diet 8.

Alternative Appetite Stimulants (If Mirtazapine Contraindicated or Ineffective)

If life expectancy is months-to-weeks and increased appetite is important for quality of life 4:

Megestrol acetate 2, 4:

• Improves appetite in 1 of 4 patients and weight in 1 of 12 patients
• Major risks: 1 in 6 develop thromboembolic phenomena; 1 in 23 will die
• Weight gain is primarily adipose tissue, not skeletal muscle
• Toxicities include edema and adrenal suppression

Dexamethasone/corticosteroids 2, 4:

• Improve appetite similarly to megestrol acetate
• Role limited to patients with life expectancy of weeks to couple months due to toxicities and declining efficacy with long-term use

Olanzapine 2:

• Emerging evidence shows appetite scores improved from 1-2 to 6-8 on 0-10 scale (p<0.001)
• ASCO guidelines currently do not recommend due to paucity of clinical trials in cachexia
• Causes considerable weight gain when used for psychiatric indications

Dronabinol/cannabinoids 4, 9, 8:

• Very limited efficacy data for appetite stimulation
• Inferior to megestrol acetate (49% vs 75% weight gain response)
• May be considered if other options fail, but evidence is weak

Clinical Monitoring and Expectations

Realistic Outcome Expectations

Evidence for appetite stimulants in non-cancer populations is limited 9, 8:

• Current data lack standardization and generalizability
• No significant weight change demonstrated in most inpatient studies 9, 8
• Numerical improvements in meal intake occur but may not reach statistical significance

Monitoring Parameters

• Weight: Weekly measurements with BMI calculation
• Dietary intake: Percentage of meals consumed
• Functional status: Assess for improvement in strength and activity
• Adverse effects: Monitor for medication-specific toxicities

Critical Pitfalls to Avoid

1. Do not add appetite stimulants without first addressing medication-induced causes: Duloxetine and opioids are likely primary contributors 2, 1

2. Avoid megestrol acetate as first-line: High thromboembolic risk (1 in 6) and mortality (1 in 23) make it inappropriate unless life expectancy is very limited 4

3. Do not use buspirone for appetite stimulation: It has no established role in appetite enhancement and carries serotonin syndrome risk when combined with duloxetine 5

4. Recognize serotonin syndrome risk: The combination of duloxetine, buspirone, and potentially mirtazapine increases risk; monitor for mental status changes, autonomic instability, and neuromuscular changes 5, 1

5. Consider non-pharmacological interventions: Dietary counseling should accompany any pharmacological approach 2